hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 22 GBX -3.93% Market Closed
Market Cap: 149.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note

hVIVO PLC
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

hVIVO PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
hVIVO PLC
LSE:HVO
Cash from Operating Activities
ÂŁ13.2m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Cash from Operating Activities
-ÂŁ137.3m
CAGR 3-Years
-29%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Cash from Operating Activities
ÂŁ1.3m
CAGR 3-Years
73%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Cash from Operating Activities
-ÂŁ3.8m
CAGR 3-Years
15%
CAGR 5-Years
5%
CAGR 10-Years
-26%
Ergomed PLC
LSE:ERGO
Cash from Operating Activities
ÂŁ19.3m
CAGR 3-Years
5%
CAGR 5-Years
50%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Cash from Operating Activities
ÂŁ3.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

hVIVO PLC
Glance View

Market Cap
149.7m GBX
Industry
Life Sciences Tools & Services

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

HVO Intrinsic Value
26.83 GBX
Undervaluation 18%
Intrinsic Value
Price

See Also

What is hVIVO PLC's Cash from Operating Activities?
Cash from Operating Activities
13.2m GBP

Based on the financial report for Jun 30, 2024, hVIVO PLC's Cash from Operating Activities amounts to 13.2m GBP.

What is hVIVO PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
46%

Over the last year, the Cash from Operating Activities growth was -38%. The average annual Cash from Operating Activities growth rates for hVIVO PLC have been 46% over the past three years .

Back to Top